Background: Continuous positive airway pressure (CPAP) is considered as the standard therapy for obstructive sleep apnea syndrome (OSAS), but some patients with OSAS are unable to accept CPAP due to nasal obstruction and poor nasal airflow. Objectives: We assessed the influence of nasal resistance before beginning CPAP treatment on the initial acceptance of CPAP in OSAS patients. Methods: The study subjects comprised 77 patients (74 males, 3 females) with primary OSAS, all of whom received CPAP treatment with nasal masks. Before trials, all subjects underwent overnight polysomnography, and nasal resistance was measured with active anterior rhinomanometry in the seated position on the first day of CPAP trial. Results: The CPAP treatment was accepted by 56 patients after the initial trials with overnight polysomnography. Body mass index, the number of apnea/hypopnea episodes per hour (apnea/hypopnea index; AHI), and the number of episodes per hour with an oxygen desaturation of >3% (oxygen desaturation index) were significantly higher (p < 0.01) and nasal resistance was lower (p = 0.003) in patients who accepted CPAP than in those who did not. Logistic regression analysis, with patient age, body mass index, Epworth sleepiness scale score, AHI, oxygen desaturation index, and nasal resistance before CPAP treatment as explanatory variables, showed that nasal resistance (OR + 0.1 Pa/cm3/s: 1.48; p = 0.002) and AHI (OR + 1 event/h: 0.93; p = 0.003) were significant factors for CPAP non-acceptance. Conclusions: Nasal resistance before the beginning of CPAP treatment has a significant effect on the acceptance of CPAP in OSAS patients, and hence, could be a predictive parameter for the initial acceptance of CPAP.

Grunstein RR, Sullivan CE: Continuous positive airway pressure for sleep breathing disorders; in Kryger MH, Roth T, Dement W (eds): Sleep Medicine. Philadelphia, Saunders, 2000, pp 894–912.
Loube DI, Gay PC, Strohl KP, Pack AI, White DP, Collop NA: Indications for positive airway pressure treatment of adult obstructive sleep apnea patients: a consensus statement. Chest 1999;115:863–866.
American Thoracic Society: Indication and standards for use of nasal continuous positive airway pressure (CPAP) in sleep apnea syndrome. Am J Respir Crit Care Med 1994;150:1738–1745.
Aloia MS, Di Dio L, Giles DE, et al: Improving compliance with nasal CPAP and vigilance in older adults with OSAHS. Sleep Breath 2001;5:13–21.
Pepin JL, Leger P, Veale D, Langevin B, Robert D, Levy P: Side effects of nasal continuous positive airway pressure in sleep apnea syndrome. Study of 193 patients in two French sleep centers. Chest 1995;107:375–381.
Lofaso F, Coste A, d’Ortho MP, Zerah-Lancner F, Delclaux C, Goldenberg F, Harf A: Nasal obstruction as a risk factor for sleep apnea syndrome. Eur Respir J 2000;16:639–643.
McNicholas WT, Tarlo S, Cole P, et al: Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 1982;126:625–628.
Young T, Finn L, Kim H: Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol 1997;99:S757–S762.
Brander PE, Soirinsuo M, Lohela P: Nasopharyngeal symptoms in patients with obstructive sleep apnea syndrome. Respiration 1999;66:128–135.
Rappai M, Collop N, Kemp S, deShazo R: The nose and sleep-disordered breathing: what we know and what we do not know. Chest 2003;124:2309–2323.
Davis SS, Eccles R: Nasal congestion: mechanisms, measurement and medications. Core information for the clinician. Clin Otolaryngol 2004;29:659–666.
Rechtschaffen A, Kales A: A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Sleep. Bethesda, National Institute of Neurological Disease and Blindness,1968.
Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–545.
Dunagan D, Georgitis J: Intranasal disease and provocation; in Kemp S, Lockey R, et al: Diagnostic Testing of Allergic Disease. New York, Marcel Dekker, 2000, pp 151–173.
Clement P: Committee report on standardization of rhinomanometry. Rhinology 1984;22:151–155.
Ohki M, Hasegawa M: Studies of transnasal pressure and airflow values in a Japanese population. Rhinology 1986;24:277–282.
Meurice JC, Marc I, Carrier G, Series F: Effects of mouth opening on upper airway collapsibility in normal sleeping subjects. Am J Respir Crit Care Med 1996;153:225–229.
Fitzpatrick MF, McLean H, Urton AM, Tan A, O’Donnel D, Driver HS: Effect of nasal or oral breathing route on upper airway resistance during sleep. Eur Respir J 2003;22:827–832.
Ohki M, Usui N, Kanazawa H, Hara I, Kwano K: Relationship between oral breathing and nasal obstruction in patients with obstructive sleep apnea. Acta Otolaryngol 1996;523(suppl):228–230.
Bachour A, Maasilta P: Mouth breathing compromises adherence to nasal continuous positive airway pressure therapy. Chest 2004;126:1248–1254.
Kiely JL, Nolan P, McNicholas WT: Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004;59:50–55.
Eccles R, Jones AS: The effect of menthol on nasal resistance to air flow. J Laryngol Otol 1983;97:705–709.
Jones AS, Willatt DJ, Durham LM: Nasal airflow: resistance and sensation. J Laryngol Otol 1989;103:909–911.
Pelletier-Fleury N, Rakotonanahary D, Fleury B: The age and other factors in the evaluation of compliance with nasal continuous positive airway pressure for obstructive sleep apnea syndrome. A Cox’s proportional hazard analysis. Sleep Med 2001;2:225–232.
Sin DD, Mayers I, Man GC, Pawluk L: Long-term compliance rates to continuous positive airway pressure in obstructive sleep apnea: a population-based study. Chest 2002;121:430–435.
Janson C, Noges E, Svedberg-Brandt S, Lindberg E: What characterizes patients who are unable to tolerate continuous positive airway pressure treatment? Respir Med 2000;94:145–149.
Rauscher H, Popp W, Wanke T, Zwick H: Acceptance of CPAP therapy for sleep apnea. Chest 1991;100:1019–1023.
Pieters T, Collard P, Aubert G, Dury M, Delguste P, Rodenstein DO: Acceptance and long-term compliance with nCPAP in patients with obstructive sleep apnoea syndrome. Eur Respir J 1996;9:939–944.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.